About ENBREL

ENBREL is the #1 prescribed biologic by rheumatologists*1

ENBREL is an anti-tumor necrosis factor biologic medication indicated for the treatment of moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis, and moderately to severely active polyarticular juvenile idiopathic arthritis.4

The experience of ENBREL is well established

  • Evaluated in RA clinical studies since 19932
    2
  • 15 years of postmarketing use in moderate to severe RA since approval in 19983
    3
  • Over 25,000 patients have been observed across 70 clinical studies4
    4
  • More than 35,000 patient-years of therapy in clinical studies across indications5
    5

A History of "1sts" Among Biologics in Each of Its Indications††

  • 1998
    1st
    approved for moderate to severe RA in DMARD**
    -refractory patients3††
  • 1999
    1st
    approved for moderately to severely active polyarticular juvenile RA (JRA)6††
  • 2002
    1st
    approved for psoriatic arthritis7††
  • 2003
    1st
    approved for ankylosing spondylitis (AS)8††
  • 2004
    1st
    approved for moderate to severe plaque psoriasis9††‡‡
  • 2008
    1st
    TNF inhibitor with a decade of post-marketing experience in RA10

 * 6-month total of IMS monthly NPA prescription data by rheumatologists. These data include only dispensed total scripts.
  Initial clinical research in RA patients began in 1993.
  Patients observed for safety across all indications. Includes global clinical trials and 4 cohort studies in the U.S. and Canada.
 ** DMARD = disease-modifying antirheumatic drug.
 †† First tumor necrosis factor (TNF) inhibitor approved in the United States.
 ‡‡ Chronic moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
 
Supportive data
Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Important Safety Considerations

More than 200,000 people have used the ENBREL Support™ card to help pay for ENBREL

Learn about our program
 
 
Close
You are leaving Enbrel.com/RheumPro
Please know that Amgen does not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2013 Amgen, Inc., Thousand Oaks, CA 91320
Close
E-mail this page to a colleague
Please correct the fields marked in red
Send
This content is for US health care professionals only. Amgen will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.
Close

Send another e-mail
Return to enbrel.com/RheumPro

Close
We're sorry.

This content is not available at this time.

Close
Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Amgen website to find information about our offices around the globe.
Close
Phil Mickelson: A PsA patient's perspective
Close
Disease activity vs. structural progression in RA
Close
Treating Moderately Active RA
Close
Rapid, Sustained Efficacy of ENBREL
Close
Improving Outcomes in Psoriatic Arthritis
Close
A look back at 15 years